{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Neck+Carcinoma+of+the+Head+and+Neck+Cancer+%28SCCHN%29&page=3", "query": { "condition": "Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 143, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Neck+Carcinoma+of+the+Head+and+Neck+Cancer+%28SCCHN%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Neck+Carcinoma+of+the+Head+and+Neck+Cancer+%28SCCHN%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T15:07:19.956Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04541108", "title": "Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Rilvegostomig", "type": "BIOLOGICAL" }, { "name": "Volrustomig", "type": "BIOLOGICAL" }, { "name": "Sabestomig", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "AZD9592", "type": "BIOLOGICAL" }, { "name": "AZD9592 + Rilvegostomig", "type": "COMBINATION_PRODUCT" }, { "name": "AZD9592 + Volrustomig", "type": "COMBINATION_PRODUCT" }, { "name": "AZD9592 + Sabestomig", "type": "COMBINATION_PRODUCT" }, { "name": "AZD9592 + Pembrolizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "Presage Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-07-26", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-11T15:07:19.956Z", "location_count": 9, "location_summary": "Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more", "locations": [ { "city": "Shreveport", "state": "Louisiana" }, { "city": "The Bronx", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04541108" }, { "nct_id": "NCT02319044", "title": "Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck" ], "interventions": [ { "name": "MEDI4736", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "MEDI4736 + Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "96 Years", "sex": "ALL", "summary": "18 Years to 96 Years" }, "enrollment_count": 267, "start_date": "2015-04-15", "completion_date": "2020-07-06", "has_results": true, "last_update_posted_date": "2020-09-29", "last_synced_at": "2026-10-11T15:07:19.956Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Yuma, Arizona • Little Rock, Arkansas + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02319044" }, { "nct_id": "NCT03349710", "title": "Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2017-12-15", "completion_date": "2019-10-14", "has_results": true, "last_update_posted_date": "2021-08-09", "last_synced_at": "2026-10-11T15:07:19.956Z", "location_count": 21, "location_summary": "Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redondo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03349710" }, { "nct_id": "NCT03468218", "title": "Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Head and Neck Carcinoma", "Paranasal Sinus Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Unresectable Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-09-18", "completion_date": "2026-10-29", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-11T15:07:19.956Z", "location_count": 2, "location_summary": "Tampa, Florida • Atlanta, Georgia", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03468218" }, { "nct_id": "NCT04943900", "title": "A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BMS-986416", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2021-08-09", "completion_date": "2025-02-27", "has_results": false, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-10-11T15:07:19.956Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04943900" }, { "nct_id": "NCT00459043", "title": "Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "ZD6474", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2007-03", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2013-07-03", "last_synced_at": "2026-10-11T15:07:19.956Z", "location_count": 3, "location_summary": "Maywood, Illinois • Boston, Massachusetts", "locations": [ { "city": "Maywood", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00459043" }, { "nct_id": "NCT05577182", "title": "Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "INCA32459-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2023-01-05", "completion_date": "2025-10-13", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-10-11T15:07:19.956Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05577182" }, { "nct_id": "NCT00542308", "title": "Zalutumumab in Non-curable Patients With SCCHN", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Squamous Cell Cancer" ], "interventions": [ { "name": "Zalutumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2008-01", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2023-08-03", "last_synced_at": "2026-10-11T15:07:19.956Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Loma Linda, California • Tampa, Florida + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00542308" }, { "nct_id": "NCT03906526", "title": "A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Squamous Cell" ], "interventions": [ { "name": "VTX-2337", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2019-07-03", "completion_date": "2022-01-24", "has_results": false, "last_update_posted_date": "2023-02-24", "last_synced_at": "2026-10-11T15:07:19.956Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03906526" }, { "nct_id": "NCT04541355", "title": "Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Locally Advanced Hypopharyngeal Squamous Cell Carcinoma", "Locally Advanced Laryngeal Squamous Cell Carcinoma", "Locally Advanced Oral Cavity Squamous Cell Carcinoma", "Locally Advanced Oropharyngeal Squamous Cell Carcinoma", "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Hypopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Lip and Oral Cavity Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVC Hypopharyngeal Carcinoma AJCC v8", "Stage IVC Laryngeal Cancer AJCC v8", "Stage IVC Lip and Oral Cavity Cancer AJCC v8", "Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Hearing Handicap Inventory for Adults - Screening", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Sodium Thiosulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Hyunseok Kang, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-10-14", "completion_date": "2023-05-31", "has_results": true, "last_update_posted_date": "2024-06-28", "last_synced_at": "2026-10-11T15:07:19.956Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04541355" } ] }